Testing golidocitinib for severe blood side effects from lung cancer immunotherapy
Treatments studied
Part of Blood & lymphatic, Cancer, Lungs & breathing clinical trials.
This trial tests a drug called golidocitinib for people with advanced lung cancer who developed serious, hard-to-treat blood-related side effects (like low white blood cells, low platelets, or anemia) from immunotherapy. The goal is to see if golidocitinib can help reverse these side effects without stopping cancer treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older with advanced non-small cell or small cell lung cancer that has not responded to standard treatments.
- You must have experienced severe, immune-related blood problems (like very low white blood cells, neutrophils, platelets, or hemoglobin) while on immunotherapy, and these problems did not improve with usual supportive care.
- Your cancer must not have gotten worse in the last two weeks, and you must be well enough to walk and care for yourself (ECOG score 0-2).
- You cannot have active autoimmune diseases, unstable heart conditions, or serious infections like HIV, hepatitis B, or tuberculosis.
- You must not have received other immunosuppressive drugs (like TNF inhibitors or other JAK inhibitors) for your blood side effects before joining.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication called golidocitinib for people who have just been diagnosed with a specific type of T-cell lymphoma and have not had any prior treatment. The goal is to see if this JAK1 inhibitor can help control the disease.
This trial tests a combination of a targeted drug (golidocitinib) with either a chemotherapy liposome or another targeted drug (chidamide) for people with peripheral T-cell lymphoma that has come back or stopped responding to treatment. The goal is to see if the combination works better than current options.
This trial tests a new pill (golidocitinib) combined with standard chemotherapy for people with a rare type of lymphoma that hasn't been treated before. The goal is to see if the combination shrinks tumors and can be given safely.
This trial tests a combination of golidocitinib (a targeted pill) and an immunotherapy drug (anti-PD-1) for people with non-small cell lung cancer that has come back or spread after prior treatment. It aims to see if this new combination can shrink tumors or stop them from growing.
This trial tests a new drug, golidocitinib, against a standard treatment chosen by your doctor for peripheral T-cell lymphoma that has come back or not responded to prior therapy. The goal is to see which approach works better for patients.
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
Hear when a new IrAE trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.